Viron Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the commercialization of novel anti-inflammatory therapeutics, today announced that Claude R. Benedict, M.D. has been appointed the Company's Senior Vice President, Clinical Development and Regulatory Affairs. Dr. Benedict brings over thirty years of medical and pharmaceutical experience to Viron, including leadership positions at Archemix Corporation and Aventis Pharmaceuticals.

 

London, Canada - Viron Therapeutics' lead drug candidate, VT-111, has been selected as one of the top 10 most promising cardiovascular drugs in development, offering significant potential for strategic partnering. The selection was made by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries.

 

Viron Therapeutics Inc., a clinical stage biopharmaceutical company, today announced the closing of a US $20M Series A financing.  This financing, combined with the additional investment of $4.5M Viron received from the Canadian government through its TPC program, brings Viron's total financing to almost US $25M.

 

Viron Therapeutics Inc. has been honoured as this year's recipient of the prestigious Prix Galien Canada award in Biotechnology. This award is one of the highest honours in the pharmaceutical and biotechnology industry and recognizes excellence in medical and scientific research and innovation.   Viron will receive the award at a gala ceremony in Montréal on November 16th.

 

LONDON, Ontario - The Honourable Joe Fontana, Minister of Labour and Housing, on behalf of the Honourable David L. Emerson, Minister of Industry, today announced a $4.9-million investment in the development of novel drug platforms to treat serious inflammatory-based diseases.

 

Viron Therapeutics Inc., a drug development company, announced today the initiation of its first Phase 2 clinical trial with its lead anti-inflammatory drug, VT-111, for the treatment of Acute Coronary Syndromes (ACS). The trial, which is approved by the U.S. FDA and Health Canada, is designed to test what could become the first in a completely new class of therapeutic compounds for the treatment of inflammatory-based disorders.

 

London, Ontario, Canada - Viron Therapeutics Inc., a London-based biopharmaceutical company, is pleased to announce that Mr. Neil Warma has accepted the position of President and CEO. Warma is returning to Canada after spending the past 12 years working in the pharmaceutical and health industries both in Basel, Switzerland and New York City.

 

London-based Viron Therapeutics Inc. has received strong endorsement from two industry leaders in support of their work developing an entirely new class of anti-inflammatory proteins. This endorsement follows very encouraging pre-clinical results that indicate a protein targeted by Viron scientists may work to prevent narrowing of the arteries that lead to heart attacks and reduce inflammation related to transplant surgery.

 

LONDON, ON - New research at Robarts Research Institute - published in the journal Proceedings of the National Academy of Science [100(8):4831-6)] - has identified a novel viral protein that strongly blocks one of the key inflammatory responses associated with conditions such as rheumatoid arthritis.

 

LONDON, ON – New research at Robarts Research Institute – presented at the 6th World Congress on Inflammation – has shown that VT-111, a drug derived from a virus, inhibits Human Endothelial, Monocyte and T-Cell Activation.